Filing Flows › Keros Therapeutics (KROS) › Q1 2026 › vs Q1 2025
Keros Therapeutics (KROS) Q1 2026 vs Q1 2025 (year over year)
Keros Therapeutics's revenue fell $211M (-100%) from $211M in Q1 2025 to $367K in Q1 2026.
Keros Therapeutics, Q1 2026: revenue $367K (-100% year over year), net loss $23.7M, operating cash flow −$3.5M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $367K | $211M | −$211M | -100% |
| Other income, net | $2.2M | $6.5M | −$4.3M | -66% |
| Net loss | $23.7M | −$148M | $172M | — |
| Costs & expenses | $26.2M | $218M | −$191M | -88% |
| Operating costs | $26.2M | $59.2M | −$32.9M | -56% |
| Research & development | $16.1M | $48.7M | −$32.6M | -67% |
| General & admin | $10.1M | $10.5M | −$350K | -3% |
| Operating cash sources | $23.7M | −$148M | $172M | — |
| Depreciation | $403K | $344K | $59K | +17% |
| Share-based compensation | $6.2M | $8.9M | −$2.7M | -30% |
| Working capital & other | $13.6M | $3.5M | $10.1M | +286% |
| Cash used in operations | $3.5M | −$161M | $165M | — |
| Net loss absorbed | $23.7M | −$148M | $172M | — |
Questions
How much did Keros Therapeutics's revenue grow year over year in Q1 2026?
Keros Therapeutics's revenue fell $211M (-100%) from $211M in Q1 2025 to $367K in Q1 2026.